Brief: Lantern Pharma Receives Notice Of Allowance For Composition Of Matter Patent Covering Drug Candidate Lp-284
13/04/2023 13:52
April 13 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES NOTICE OF ALLOWANCE FOR
COMPOSITION OF
MATTER PATENT COVERING DRUG CANDIDATE LP-284
* LANTERN PHARMA INC - EXPECTS RESULTING LP-284 PATENT WILL
BE
ORANGE BOOK-LISTABLE WITH AN ANTICIPATED EXPIRATION OF EARLY
2039
* LANTERN PHARMA INC - ANTICIPATES RECEIVING SIMILAR PATENT
RIGHTS
FOR LP-284 IN EUROPE, JAPAN, INDIA, CHINA, AUSTRALIA, CANADA,
AND KOREA
Source text for Eikon: ID:nBwb0w5xta
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview